Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Neutral 74.5%

Neg 0% Neu 74.5% Pos 0%

Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $30 to $23.